Mitochondrial Dysfunction in Cardiorenal Syndrome
11 Department of Emergency and Critical Care Medicine, The University of Tokyo , Tokyo, Japan .
Significance:
Acute kidney injury (AKI) has a significant impact on the outcomes of critically ill patients, although no effective and specific treatment against AKI is currently available in the clinical setting. It is assumed that reactive oxygen species production by the mitochondria plays a crucial role in renal damage especially caused by cellular apoptosis. Mitochondrial injury in the heart is reported as an important determinant of myocardial contractility. Clinical epidemiological data indicate that remote organ effects induced by AKI, especially organ cross talk between the kidney and heart, might contribute to the poor outcome of AKI patients.
Recent Advances:
Cardiorenal syndrome (CRS) has recently been defined based on clinical observations that acute and chronic heart failure causes kidney injury and AKI and that chronic kidney disease worsens heart diseases. Possible pathways that connect these two organs have been suggested; however, the precise mechanisms are still unclarified. Mitochondrial injury in the kidney and heart has been shown as a crucial pathway of AKI and acute heart failure by several animal studies.
Critical Issues:
Clinical evidence clearly shows cardiorenal interactions in clinically ill patients, but evidence for distant organ effects of AKI on the heart is lacking. We recently found dysregulation of mitochondrial dynamics caused by increased Drp1 expression and cellular apoptosis of the heart in an experimental AKI animal model of renal ischemia-reperfusion.
Future Directions:
Precise mechanisms that induce cardiac mitochondrial injury in AKI remain unclarified. A recently suggested concept of mitochondrial hormesis may need to be considered in chronic cardiorenal interaction. Identifying the role of mitochondrial injury for CRS will enable the development of novel interventional approaches to reduce mortality associated with AKI. Antioxid. Redox Signal. 25, 200-207.
Insights
Acute kidney injury (AKI) can harm the heart, leading to cardiorenal syndrome. Our study shows AKI causes heart mitochondrial damage and apoptosis, suggesting new treatment targets.
Area of Science:
- Cardiorenal physiology and pathology
- Mitochondrial dynamics and apoptosis
- Organ cross-talk in critical illness
Background:
- Acute kidney injury (AKI) significantly impacts critically ill patients, with limited specific treatments.
- Mitochondrial dysfunction and reactive oxygen species are implicated in AKI and renal damage.
- Cardiorenal syndrome (CRS) describes interactions where heart and kidney conditions exacerbate each other.
Purpose of the Study:
- To investigate the impact of AKI on cardiac mitochondrial dynamics and apoptosis.
- To explore the mechanisms underlying remote organ effects of AKI on the heart.
- To identify potential therapeutic targets for AKI-induced cardiorenal complications.
Main Methods:
- Utilized an experimental animal model of renal ischemia-reperfusion injury to induce AKI.
- Assessed cardiac mitochondrial dynamics, focusing on Drp1 expression.
- Evaluated markers of cellular apoptosis in the heart tissue.
Main Results:
- Demonstrated dysregulation of mitochondrial dynamics in the heart following AKI.
- Observed increased Drp1 expression, a key regulator of mitochondrial fission.
- Confirmed elevated levels of cellular apoptosis in cardiac tissue from the AKI model.
Conclusions:
- AKI induces significant cardiac mitochondrial injury and apoptosis, contributing to cardiorenal interactions.
- Mitochondrial dynamics dysregulation is a key mechanism in AKI-induced heart damage.
- Understanding these mechanisms is crucial for developing novel interventions for CRS and reducing AKI-related mortality.
Related Concept Videos
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:17Pathophysiology of Heart Failure
01:24Chronic Kidney Disease II: Clinical Manifestations
01:22Heart Failure Drugs: Diuretics
01:30Cardiomyopathy II: Dilated Cardiomyopathy